Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

Sep. 17, 2024 — With the help of NASA's Hubble Space Telescope, an international team of scientists has found more black holes in the early universe than has previously been reported.

Black Friday deals are near, and yes, you read that right. Amazon has just confirmed the dates for its second Prime Day sale, which will take place on October 8 and 9. This kicks off the 2024 ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’s Kisqali (ribociclib), allowing it to be used as an add-on therapy in early breast cancer patients.

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence. The Food and Drug Administration (FDA) has approved ...

Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE. This late-breaking data from this four-year post-hoc analysis was presented at ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

(RTTNews) - Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III NATALEE trial of investigational Kisqali (ribociclib ...

This risk is different for everyone, depending on many factors, but should not be underestimated," said Valarie Worthy, co-founder & vice president of community outreach and engagement, Touch, The ...